Ioana Emilia Pavel

Prof. Dr. Ioana Emilia Pavel

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
Iulia Andreea PinzaruIulia Andreea Pinzaru
Iulia Andreea Pinzaru
DCDorina Coricovac
Dorina Coricovac
CRISTINA ADRIANA DEHELEANCRISTINA ADRIANA DEHELEAN
CRISTINA ADRIANA DEHELEAN
Elena Alina MoacaElena Alina Moaca
Elena Alina Moaca
MMMarius Mioc
Marius Mioc
Codruta SoicaCodruta Soica
Codruta Soica

17 January 2018 in ACS Omega
Verified
Journal Article
Open access
KSKraig E. Strayer
Kraig E. Strayer
HAHeather M. Antonides
Heather M. Antonides
MJMatthew Juhascik
Matthew Juhascik
RDRaminta Daniulaityte
Raminta Daniulaityte
ISIoana Sizemore
Ioana Sizemore
The United States and numerous other countries worldwide are currently experiencing a public health crisis due to the abuse of illicitly manufactured fentanyl (IMF) and its analogues. This manuscript describes the development of a liquid chromatography-tandem mass spectrometry-based method for the multiplex detection of N = 24 IMF analogues and metabolites in whole blood at concentrations as low as 0.1–0.5 ng mL–1. These available IMFs were fentanyl, norfentanyl, furanyl norfentanyl, remifentanil acid, butyryl norfentanyl, remifentanil, acetyl fentanyl, alfentanil, AH-7921, U-47700, acetyl fentanyl 4-methylphenethyl, acrylfentanyl, para-methoxyfentanyl, despropionyl fentanyl (4-ANPP), furanyl fentanyl, despropionyl para-fluorofentanyl, carfentanil, (±)-cis-3-methyl fentanyl, butyryl fentanyl, isobutyryl fentanyl, sufentanil, valeryl fentanyl, para-fluorobutyryl fentanyl, and para-fluoroisobutyryl fentanyl. Most IMF analogues (N = 22) could be easily distinguished from one another; the isomeric forms butyryl/isobutyryl fentanyl and para-fluorobutyryl/para-fluoroisobutyryl fentanyl could not be differentiated. N = 13 of these IMF analogues were quantified for illustrative purposes, and their forensic quality control standards were also validated for limit of detection (0.017–0.056 ng mL–1), limit of quantitation (0.100–0.500 ng mL–1), selectivity/sensitivity, ionization suppression/enhancement (87–118%), process efficiency (60–95%), recovery (64–97%), bias (80%). This flexible, time- and cost-efficient method was successfully implemented at the Montgomery County Coroner’s Office/Miami Valley Regional Crime Laboratory in Dayton, Ohio, where it aided in the analysis of N = 725 postmortem blood samples collected from February 2015 to November 2016.

31 July 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
KKKyra Kaiser
Kyra Kaiser
VDVictoire Delattre
Victoire Delattre
VFVictoria Frost
Victoria Frost
GBGregory Willaim Buck
Gregory Willaim Buck
JPJulianne V. Phu
Julianne V. Phu
ISIoana Sizemore
Ioana Sizemore
Antibiotic resistance in bacteria is a major problem worldwide that costs 55 billion USD annually for extended hospitalization, resource utilization, and additional treatment expenditures in the United States. This review examines the roles and forms of silver (e.g., bulk Ag, silver salts (AgNO3), and colloidal Ag) from antiquity to the present, and its eventual incorporation as silver nanoparticles (AgNPs) in numerous antibacterial consumer products and biomedical applications. The AgNP fabrication methods, physicochemical properties, and antibacterial mechanisms in Gram-positive and Gram-negative bacterial models are covered. The emphasis is on the problematic ESKAPE pathogens and the antibiotic-resistant pathogens of the greatest human health concern according to the World Health Organization. This review delineates the differences between each bacterial model, the role of the physicochemical properties of AgNPs in the interaction with pathogens, and the subsequent damage of AgNPs and Ag+ released by AgNPs on structural cellular components. In closing, the processes of antibiotic resistance attainment and how novel AgNP–antibiotic conjugates may synergistically reduce the growth of antibiotic-resistant pathogens are presented in light of promising examples, where antibiotic efficacy alone is decreased.

13 September 2011 in Journal of Chemical Education
Verified
Journal Article
Closed access
ISIoana Sizemore
Ioana Sizemore
KAKhadijeh S. Alnajjar
Khadijeh S. Alnajjar
JMJennifer L. Monahan
Jennifer L. Monahan
ASAdam Stahler
Adam Stahler
NHNora E. Hunter
Nora E. Hunter
DDDavid A. Dolson
David A. Dolson

1 September 2019 in International Journal of Drug Policy
Verified
Journal Article
Closed access
RDRaminta Daniulaityte
Raminta Daniulaityte
RCRobert R. Carlson
Robert R. Carlson
MJMatthew Juhascik
Matthew Juhascik
KSKraig E. Strayer
Kraig E. Strayer
ISIoana Sizemore
Ioana Sizemore

29 October 2014 in Journal of Chemical Education
Verified
Journal Article
Closed access
SPSesha L. A. Paluri
Sesha L. A. Paluri
MEMichelle L. Edwards
Michelle L. Edwards
NLNhi H. Lam
Nhi H. Lam
EWElizabeth M. Williams
Elizabeth M. Williams
AMAllie Meyerhoefer
Allie Meyerhoefer
ISIoana Sizemore
Ioana Sizemore